-
Sangre 02/1987; 32(3):273-80.
-
Sangre 02/1987; 32(4):416-22.
-
Ginecología y obstetricia de México 09/1984; 52(328):187-90.
-
Gaceta medica de Mexico 09/1983; 119(8):326-9. · 0.22 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: At the present time, it is possible to achieve up to a 95% complete remission in childhood acute lymphoblastic leukemia, using the combination of vincristine and prednisone. Nevertheless, it has not been possible to reproduce these results in the adult. For this reason, a third drug, in this case adriamycin in a low dose, was added to the vincristine-prednisone combination in the treatment of adult acute lymphoblastic leukemia (ALL). Complete remission was achieved in 45 of the 50 patients (90%). The median duration of remission was 23 months and the median survival time in this group was 31 months. The complications were minimal and the tolerance was good. From the point of view of our results and others reported in the literature, we consider that the combination of vincristine, prednisone, and adriamycin is a useful method for induction of remission of adult ALL.
Medical and Pediatric Oncology 02/1983; 11(2):141-5.
-
Revista medica de Chile 04/1982; 110(3):255-62. · 0.33 Impact Factor
-
Sangre 02/1982; 27(5):953-8.
-
Revista medica de Chile 07/1981; 109(6):527-31. · 0.33 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: 124 adult patients with acquired aplastic anaemia (A.A.) were studied. 54 presented as severe A.A. (mean survival of the whole group, 2.7 months and in those who died, 2.5 months; mortality 88.8%) while 70 were mild (mean survival of the whole group, 27.2 months and in those who died , 22.7 months; mortality, 28.5%). Sixty-four did not live long enough to have adequate therapeutic trials or developed severe hepatic failure which made it impossible to continue treatment. The effectiveness of 78 therapeutic periods of treatment in the 60 evaluable cases was analyzed as to aetiology and severity. A response was obtained in 31 (40%), of which 24 were with oxymethalone; 17 showed improvement after 6 months of treatment. No conclusions could be drawn as to the effectiveness of methalone, cyclophosphamide and prednisone because of the limited number of treatments. In severe A.A. only one of 13 treatments was effective, whereas 30 of the 65 used in mild A.A. gave a response. Oxymethalone was used in 23 out of 41 (56%). The aetiology, sex and age appeared to have no influence on the response of the 60 patients analyzed. The only factor which appears useful for prognosis as to the effectiveness of treatment is the severity of the case.
Acta Haematologica 02/1980; 64(1):18-24. · 1.35 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: 124 adult patients with acquired aplastic anaemia (A.A.) were studied. 54 presented as severe A.A. (mean survival of the whole group, 2.7 months and in those who died, 2.5 months; mortality 88.8%) while 70 were mild (mean survival of the whole group, 27.2 months and in those who died, 22.7 months; mortality, 28.5%). Sixty-four did not live long enough to have adequate therapeutic trials or developed severe hepatic failure which made it impossible to continue treatment. The effectiveness of 78 therapeutic periods of treatment in the 60 evaluable cases was analyzed as to aetiology and severity. A response was obtained in 31 (40%), of which 24 were with oxymethalone; 17 showed improvement after 6 months of treatment. No conclusions could be drawn as to the effectiveness of methalone, cyclophosphamide and prednisone because of the limited number of treatments. In severe A.A. only one of 13 treatments was effective, whereas 30 of the 65 used in mild A.A. gave a response. Oxymethalone was used in 23 out of 41 (56%). The aetiology, sex and age appeared to have no influence on the response of the 60 patients analyzed. The only factor which appears useful for prognosis as to the effectiveness of treatment is the severity of the case.
Acta Haematologica. 08/1970; 64(1):18-24.
-
[show abstract]
[hide abstract]
ABSTRACT: We evaluated the use of heparin in continuous flow centrifugation by continuous infusion. Doses were modified by assessment of the anticoagulant effect by the thrombin time dilution test (TTDT). Heparin is an efficient anticoagulant in continuous flow centrifugation and the TTDT is an effective and reliable method for control. The initial dose in leukapheresis is one unit per milliliter of blood during the first hour, then one-half the dose during the next hour, and then a one-quarter of the dose until the procedure is completed. A TTDT performed every 30 to 60 minutes will indicate whether the heparin dose should be modified. For plasmapheresis, it is necessary to determine the specific dose for each patient. There was no case of bleeding or extracorporeal coagulation of the blood.
Transfusion 22(5):384-7. · 3.22 Impact Factor
-
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 33(3):289-91. · 0.42 Impact Factor
-
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 34(3):223-8. · 0.42 Impact Factor
-
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 34(2):113-9. · 0.42 Impact Factor
-
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 35(4):309-14. · 0.42 Impact Factor
-
Archivos de investigación médica 15(1):55-65.
-
[show abstract]
[hide abstract]
ABSTRACT: Seven members of 3 families developed acute leukemia (AL) between 1969 and 1988. The clinical presentation, course and response to treatment were no different to non-familial cases of AL. The morphology subtypes were identical in every family: myeloblastic in 3 and lymphoblastic in 4. Leukemogenic factors (radiation, drugs use or benzene exposure) were excluded in these patients. Genetical and environmental factors might have a role in the pathogenesis but no clear evidence has been established.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 42(2):135-7. · 0.42 Impact Factor
